Key Figures Q2 2021

SEK m, unless otherwise stated

2021

Apr-Jun

2020

Apr-Jun

2021

Jan-Jun

2020

Jan-Jun

2020

Jan-Dec

Net revenues

142.8

179.1

275.1

354.2

663.6

Cost of goods sold

-18.1

-19.9

-37.4

-39.9

-65.6

Operating expenses

-178.7

-172.5

-328.7

-293.6

-617.9

EBIT

-54.0

-13.3

-90.9

20.7

-19.9

EBIT margin, %

-37.8

-7.4

-33.1

5.8

-3.0

EBITDA

-41.1

-9.0

-65.2

30.1

19.0

Earnings per share, before dilution, SEK

-2.15

-0.94

-3.07

1.44

-2.45

Earnings per share, after dilution, SEK

-2.15

-0.94

-3.07

1.44

-2.45

Cash flow from operating activities

-20.9

-7.2

-68.7

40.9

16.8

Cash and cash equivalents

679.7

677.2

679.7

677.2

505.3

Net revenues and EBIT per segment Q2 2021

SEK m

Net Revenues

EBIT

 

2021 Apr-Jun

2020 Apr-Jun

2021 Jan-Jun

2020 Jan-Jun

2020 Jan-Dec

2021 Apr-Jun

2020 Apr-Jun

2021 Jan-Jun

2020 Jan-Jun

2020 Jan-Dec

ZUBSOLV® US

126.0

172.5

252.8

336.4

623.3

-

-

-

-

-

US Pharma – total

126.0

172.5

252.8

336.4

623.3

61.6

88.8

127.7

164.5

331.2

Digital Therapeutics (DTx) product sales

0.3

-

0.4

-

0.0

-

-

-

-

-

Digital Therapeutics (DTx) – total

0.3

-

0.4

-

0.0

-51.6

-35.5

-110.5

-47.6

-175.4

Abstral® royalties

14.3

3.5

17.0

12.2

29.7

-

-

-

-

-

Edluar® royalties

2.3

3.1

4.9

5.5

10.4

-

-

-

-

-

ZUBSOLV® - ex US

-

-

-

0.1

0.1

-

-

-

-

-

HQ & Pipeline segment - total

16.5

6.6

21.9

17.8

40.2

-63.9

-66.6

-108.2

-96.2

-175.8

Total

142.8

179.1

275.1

354.2

663.6

-54.0

-13.3

-90.9

20.7

-19.9


Cash flow Q2 2021

 

SEK m

2021

Apr-Jun

2020

Apr-Jun

2021

Jan-Jun

2020

Jan-Jun

2020

Jan-Dec

Cash flow from operating activities

-20.9

-7.2

-68.7

40.9

16.8

Investment activities

-13.1

-106.0

-29.3

-109.9

-189.2

Financing activities

-3.5

-33.9

258.2

-102.7

-111.3

Cash flow (excl exchange rate differences)

-37.5

-147.1

160.1

-171.7

-283.7

Liquid funds

679.7

677.2

679.7

677.2

505.3